Community Assistant Professor, Department of Biomedical Sciences
Contact Information
Email:Biosketch
Josh Bartoe, DVM, is currently Vice President of Ophthalmology Services and Attending Veterinarian at Northern Biomedical Research, headquartered in Norton Shores, Michigan. NBR is a contract research organization, based on the central western coast of Michigan, focused on targeted delivery expertise for CNS, ophthalmology, cardiology, and orthopedic indications. He is also the Director of Finance for Northern Biomolecular Services, also of Norton Shores. NBS is a contract research analytical laboratory focused on providing comprehensive, GLP-compliant qPCR-qRT-PCR assays to support development of gene, cell, and other biological therapeutics.
Dr. Bartoe is a Diplomate of the American College of Veterinary Ophthalmologists and started his career in academic medicine with Michigan State University College of Veterinary Medicine. During his 10 years with MSU, he also provided consulting ophthalmology services to MPI Research. He left MSU to become the Director of Ophthalmology Services at MPI in 2014. Following the Charles River acquisition of MPI, Dr. Bartoe was selected to lead the global CRL ocular center of excellence and was promoted to Senior Director of Ophthalmology Services for the Mattawan, Michigan, site. He has authored more than 30 peer-reviewed manuscripts focused primarily on the ocular gene therapy space, along with 6 textbook chapters. He is an active member of the Association for Research in Vision and Ophthalmology, American Society of Gene and Cell Therapy, Society of Toxicology, and the American College of Veterinary Ophthalmologists.
-
Education and Training
- MS 2001, Biology, The Ohio State University
- DVM 2001, The Ohio State University
- BS 1997, Biology, University of Minnesota-Duluth
-
Research
- Veterinary Toxicology
- Ophthalmology
-
Publications
Booler H., Ramos M.F., Bartoe J., Teixeira L. The Eye Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 4: Toxicologic Pathology of Organ Systems. 2024:739-832.
Booler H.S., Lejeune T., Turner O., Saravanan C., Bartoe J.T., Bolon B. Pathology Findings and In-Life Correlates in the Nonclinical Development of Adeno-Associated Virus (AAV)-Based Retinal Gene Therapies Toxicologic Pathology. 2024;52:506-522.
Schafer K.A., Atzpodien E., Bach U., Bartoe J., Booler H., Brassard J., Farman C., Kochi M., Lejeune T., Meseck E., Nolte T., Ramos M., Short B., Sorden S., Teixeira L., Turner O., Walling B., Yekkala K., Yoshizawa K. International Harmonization of Nomenclature and Diagnostic Criteria (INHAND): Nonproliferative and Proliferative Lesions of Nonrodent Ocular Tissues Toxicologic Pathology. 2024;52:368-455.
Meany E.L., Andaya R., Tang S., Kasse C.M., Fuji R.N., Grosskopf A.K., d'Aquino A.L., Bartoe J.T., Ybarra R., Shelton A., Pederson Z., Hu C., Leung D., Nagapudi K., Ubhayakar S., Wright M., Yen C.W., Appel E.A. Injectable Polymer-Nanoparticle Hydrogel for the Sustained Intravitreal Delivery of Bimatoprost Advanced Therapeutics. 2023;6
Miyadera K., Santana E., Roszak K., Iffrig S., Visel M., Iwabe S., Boyd R.F., Bartoe J.T., Sato Y., Gray A., Ripolles-Garcia A., Dufour V.L., Byrne L.C., Flannery J.G., Beltran W.A., Aguirre G.D. Targeting ON-bipolar cells by AAV gene therapy stably reverses LRIT3-congenital stationary night blindness Proceedings of the National Academy of Sciences of the United States of America. 2022;119
Pavlou M., Schön C., Occelli L.M., Rossi A., Meumann N., Boyd R.F., Bartoe J.T., Siedlecki J., Gerhardt M.J., Babutzka S., Bogedein J., Wagner J.E., Priglinger S.G., Biel M., Petersen-Jones S.M., Büning H., Michalakis S. Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders EMBO Molecular Medicine. 2021;13
Zeng Y., Boyd R., Bartoe J., Wiley H.E., Marangoni D., Wei L.L., Sieving P.A. “Para-retinal” Vector Administration into the Deep Vitreous Enhances Retinal Transgene Expression Molecular Therapy - Methods and Clinical Development. 2020;18:422-427.
Park S.A., Sledge D., Monahan C., Bartoe J.T., Komáromy A.M. Primary angle-closure glaucoma with goniodysgenesis in a Beagle dog BMC Veterinary Research. 2019;15(1)
Pierce K.E., Curran P.G., Zelinka C.P., Fischer A.J., Petersen-Jones S.M., Bartoe J.T. Sildenafil Administration in Dogs Heterozygous for a Functional Null Mutation in Pde6a: Suppressed Rod-Mediated ERG Responses and Apparent Retinal Outer Nuclear Layer Thinning Advances in Experimental Medicine and Biology. 2019;1185:371-376.
Bartoe J.T., Cook C.S., Bussieres M., Munger R.J., Brown M.H. Harmonization of lesion nomenclature in laboratory animals Standards for Ocular Toxicology and Inflammation. 2018:141-168.
Berkowski W., Langohr I., Pease A., Bartoe J. Microphthalmia, corneal dermoids, and congenital anomalies resembling goldenhar syndrome in a cat Journal of the American Veterinary Medical Association. 2018;252(3):324-329.
Gilger B.C., Bartoe J.T., Seth Eaton J., Boyd R. Standard operating procedures for common laboratory animal ocular procedures Standards for Ocular Toxicology and Inflammation. 2018:27-44.
Gilger B.C., Brown M.H., Munger R.J., Bartoe J.T., Bussieres M., Cook C.S. Standards for conducting ophthalmic examinations in laboratory animals Standards for Ocular Toxicology and Inflammation. 2018:141-168.
Mowat F.M., Bartoe J.T. Adnexal Surgery Equine Surgery, Fifth Edition. 2018:927-956.
Stonex T.M., Bartoe J.T., Aguirre G.D. Lack of consensus on consensual response Veterinary Ophthalmology. 2018;21(1):104-107.
Wilkie D.A., Gilger B.C., Bartoe J.T. Standards for conducting ophthalmic examinations in laboratory animals Standards for Ocular Toxicology and Inflammation. 2018:1-25.
Mowat F., Occelli L., Bartoe J., Gervais K., Bruewer A., Querubin J., Dinculescu A., Boye S., Hauswirth W., Petersen-Jones S. Gene therapy in a large animal model of PDE6A-retinitis pigmentosa Frontiers in Neuroscience. 2017;11(JUN)
Winkler P.A., Davis J.A., Petersen-Jones S.M., Venta P.J., Bartoe J.T. A tool set to allow rapid screening of dog families with PRA for association with candidate genes Veterinary Ophthalmology. 2017;20(4):372-376.
Boyd R., Boye S., Conlon T., Erger K., Sledge D., Langohr I., Hauswirth W., Komáromy A., Petersen-Jones S., Bartoe J. Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs Gene Therapy. 2016;23(6):548-556.
Boyd R., Sledge D., Boye S., Hauswirth W., Komáromy A., Petersen-Jones S., Bartoe J. Erratum: Photoreceptor-targeted gene delivery using intravitreally administered AAV vectors in dogs (Gene Therapy (2016) 23 (223-230)) DOI:10.1038/gt.2015.96) Gene Therapy. 2016;23(4):400.
Boyd R.F., Sledge D.G., Boye S.L., Hauswirth W.W., Komáromy A.M., Petersen-Jones S.M., Bartoe J.T. Photoreceptor-targeted gene delivery using intravitreally administered AAV vectors in dogs Gene Therapy. 2016;23(2):223-230.
Marangoni D., Bush R.A., Zeng Y., Wei L.L., Ziccardi L., Vijayasarathy C., Bartoe J.T., Palyada K., Santos M., Hiriyanna S., Wu Z., Colosi P., Sieving P.A. Ocular and systemic safety of a recombinant AAV8 vector for X-linked retinoschisis gene therapy: GLP studies in rabbits and Rs1-KO mice Molecular Therapy Methods and Clinical Development. 2016;5
Pierce K.E., Wilkie D.A., Gemensky-Metzler A.J., Curran P., Townsend W.M., Petersen-Jones S.M., Bartoe J.T. An association between systemic cyclosporine administration and development of acute bullous keratopathy in cats Veterinary ophthalmology. 2016;19:77-85.
Dawson-Baglien E., Winkler P., Bruewer A., Petersen-Jones S., Bartoe J. Isolation and cultivation of canine uveal melanocytes Veterinary ophthalmology. 2015;18(4):285-290.
Minella A.L., Mowat F.M., Willett K.L., Sledge D., Bartoe J.T., Bennett J., Petersen-Jones S.M. Differential targeting of feline photoreceptors by recombinant adeno-associated viral vectors: Implications for preclinical gene therapy trials Gene Therapy. 2014;21(10):913-920.
Mowat F.M., Gornik K.R., Dinculescu A., Boye S.L., Hauswirth W.W., Petersen-Jones S.M., Bartoe J.T. Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach Gene Therapy. 2014;21(1):96-105.
Winkler P., Gornik K., Ramsey D., Dubielzig R., Venta P., Petersen-Jones S., Bartoe J. A partial gene deletion of SLC45A2 causes oculocutaneous albinism in doberman pinscher dogs PLoS ONE. 2014;9(3)
Annear M.J., Gornik K.R., Venturi F., Hauptman J.G., Bartoe J.T., Petersen-Jones S.M. Reproducibility of an objective four-choice canine vision testing technique that assesses vision at differing light intensities Veterinary Ophthalmology. 2013;16(5):324-328.
Annear M.J., Mowat F.M., Bartoe J.T., Querubin J., Azam S.A., Basche M., Curran P., Smith A.J., Bainbridge J.W.B., Ali R.R., Petersen-Jones S.M. Successful gene therapy in older Rpe65-deficient dogs following subretinal injection of an adeno-associated vector expressing RPE65 Human Gene Therapy. 2013;24(10):883-893.
Bruewer A., Mowat F., Bartoe J., Boye S., Hauswirth W., Petersen-Jones S. Evaluation of Lateral Spread of Transgene Expression following Subretinal AAV-Mediated Gene Delivery in Dogs PLoS ONE. 2013;8(4)
Mowat F.M., Breuwer A.R., Bartoe J.T., Annear M.J., Zhang Z., Smith A.J., Bainbridge J.W.B., Petersen-Jones S.M., Ali R.R. RPE65 gene therapy slows cone loss in Rpe65-deficient dogs Gene Therapy. 2013;20(5):545-555.
Winkler P.A., Bartoe J.T., Quinones C.R., Venta P.J., Petersen-Jones S.M. Exclusion of eleven candidate genes for ocular melanosis in cairn terriers Journal of Negative Results in BioMedicine. 2013;12(1)
Winkler P.A., Ekenstedt K.J., Occelli L.M., Frattaroli A.V., Bartoe J.T., Venta P.J., Petersen-Jones S.M. A large animal model for CNGB1 autosomal recessive retinitis pigmentosa PLoS ONE. 2013;8(8)
Mowat F., Bartoe J.T. Adnexal Surgery Equine Surgery, Fourth Edition. 2012:744-770.
Petersen-Jones S., Annear M., Bartoe J., Mowat F., Barker S., Smith A., Bainbridge J., Ali R. Gene augmentation trials using the Rpe65-deficient dog: Contributions towards development and refinement of human clinical trials Advances in Experimental Medicine and Biology. 2012;723:177-182.
Townsend W.M., Jacobi S., Bartoe J.T. Phacoemulsification and implantation of foldable +14 diopter intraocular lenses in five mature horses Equine Veterinary Journal. 2012;44(2):238-243.
Annear M.J., Bartoe J.T., Barker S.E., Smith A.J., Curran P., Bainbridge J.W., Ali R.R., Petersen-Jones S.M. Gene therapy in the second eye of RPE65-deficient dogs improves retinal function Gene Therapy. 2011;18(1):53-61.
Petersen-Jones S.M., Bartoe J.T., Fischer A.J., Scott M., Boye S.L., Chiodo V., Hauswirth W.W. AAV retinal transduction in a large animal model species: Comparison of a self-complementary AAV2/5 with a single-stranded AAV2/5 vector Molecular Vision. 2009;15:1835-1842.
Bartoe J.T., Brightman A.H., Davidson H.J. Modified lateral orbitotomy for vision-sparing excision of a zygomatic mucocele in a dog: Case report Veterinary Ophthalmology. 2007;10(2):127-131.
Bartoe J., Davidson H., Horton M., Jung Y., Brightman A. The effects of bimatoprost and unoprostone isopropyl on the intraocular pressure of normal cats Veterinary Ophthalmology. 2005;8(4):247-252.
Clark-Price S., Cox J., Bartoe J., Davis E. Use of dapsone in the treatment of Pneumocystis carinii pneumonia in a foal Journal of the American Veterinary Medical Association. 2004;224(3):407-410+371.
Zhang W., Nisbet J.W., Albrecht B., Ding W., Kashanchi F., Bartoe J.T., Lairmore M.D. Human T-lymphotropic virus type 1 p30<sup>II</sup> regulates gene transcription by binding CREB binding protein/p300 Journal of Virology. 2001;75(20):9885-9895.
Bartoe J.T., Albrecht B., Collins N.D., Robek M.D., Ratner L., Green P.L., Lairmore M.D. Functional role of pX open reading frame II of human T-lymphotropic virus type 1 in maintenance of viral loads in vivo Journal of Virology. 2000;74(3):1094-1100.
Lairmore M.D., Albrecht B., D'Souza C., Nisbet J.W., Ding W., Bartoe J.T., Green P.L., Zhang W. In vitro and in vivo functional analysis of human T cell lymphotropic virus type 1 pX open reading frames I and II AIDS Research and Human Retroviruses. 2000;16(16):1757-1764.
Zhang W., Nisbet J.W., Bartoe J.T., Ding W., Lairmore M.D. Human T-lymphotropic virus type 1 p30<sup>II</sup> functions as a transcription factor and differentially modulates CREB-responsive promoters Journal of Virology. 2000;74(23):11270-11277.